Implementation of a Re-engagement Program for Hepatitis C Patients Lost to Follow-up in Argentina.
Launched by HOSPITAL EL CRUCE · Apr 17, 2024
Trial Information
Current as of July 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on helping people in Argentina who have been diagnosed with chronic Hepatitis C (HCV) but are not currently receiving treatment. Hepatitis C is a serious infection that can lead to severe health problems, and many patients are unaware of its urgency, often because they feel fine and do not see the need for treatment. The trial aims to reconnect these patients with healthcare services and encourage them to start treatment, which has improved significantly in recent years.
To participate in this trial, individuals need to be over 18 years old and have a diagnosis of chronic Hepatitis C. This study is not yet recruiting participants, but once it begins, eligible individuals can expect to receive support and information to help them understand their condition and the importance of treatment. The ultimate goal is to make it easier for people to access the care they need, which is a crucial step toward eliminating Hepatitis C as a public health concern in Argentina.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All of the following inclusion criteria must be met.
- • Over 18 years old
- • Diagnosis of chronic HCV
- Exclusion Criteria:
- • no
About Hospital El Cruce
Hospital El Cruce is a leading healthcare institution dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. Located in Buenos Aires, Argentina, the hospital is renowned for its multidisciplinary approach, combining cutting-edge technology with a commitment to evidence-based practices. As a clinical trial sponsor, Hospital El Cruce prioritizes patient safety and ethical standards while fostering collaboration with researchers and healthcare professionals. The institution aims to contribute valuable insights to the medical community by exploring new therapies and treatment modalities across various fields, ultimately enhancing the quality of care for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported